MCID: HYP076
MIFTS: 56

Hyperthyroidism

Categories: Immune diseases, Endocrine diseases, Genetic diseases, Rare diseases

Aliases & Classifications for Hyperthyroidism

MalaCards integrated aliases for Hyperthyroidism:

Name: Hyperthyroidism 12 72 36 28 51 40 41 14 69
Overactive Thyroid 12 59

Classifications:



External Ids:

Disease Ontology 12 DOID:7998
ICD10 32 E05.9
MeSH 41 D006980
NCIt 46 C3123
KEGG 36 H01645
UMLS 69 C0020550

Summaries for Hyperthyroidism

MedlinePlus : 40 Your thyroid is a butterfly-shaped gland in your neck, just above your collarbone. It is one of your endocrine glands, which make hormones. Thyroid hormones control the rate of many activities in your body. These include how fast you burn calories and how fast your heart beats. All of these activities are your body's metabolism. If your thyroid is too active, it makes more thyroid hormones than your body needs. This is called hyperthyroidism. Hyperthyroidism is more common in women, people with other thyroid problems, and those over 60 years old. Graves' disease, an autoimmune disorder, is the most common cause. Other causes include thyroid nodules, thyroiditis, consuming too much iodine, and taking too much synthetic thyroid hormone. The symptoms can vary from person to person. They may include Being nervous or irritable Mood swings Fatigue or muscle weakness Heat intolerance Trouble sleeping Hand tremors Rapid and irregular heartbeat Frequent bowel movements or diarrhea Weight loss Goiter, which is an enlarged thyroid that may cause the neck to look swollen To diagnose hyperthyroidism, your doctor will do a physical exam, look at your symptoms, and do thyroid tests. Treatment is with medicines, radioiodine therapy, or thyroid surgery. No single treatment works for everyone. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Hyperthyroidism, also known as overactive thyroid, is related to graves' disease and myxedema. An important gene associated with Hyperthyroidism is TSHR (Thyroid Stimulating Hormone Receptor), and among its related pathways/superpathways are Peptide ligand-binding receptors and Allograft rejection. The drugs Acetylcholine and Prednisolone have been mentioned in the context of this disorder. Affiliated tissues include thyroid, eye and bone, and related phenotypes are Increased HPV16-GFP infection and endocrine/exocrine gland

Disease Ontology : 12 A thyroid gland disease that involves an over production of thyroid hormone.

PubMed Health : 59
About overactive thyroid: The thyroid gland is a part of the body’s endocrine (hormone) system – which is made up of the glands that help regulate many of the body’s different functions. An overactive thyroid produces too much of the thyroid hormone thyroxine, which causes some of these functions to speed up. “Hyperthyroidism” is the medical term for an overactive thyroid gland.Too little thyroxine reverses the process and slows down the body’s functions. This can be caused by an underactive thyroid, a condition also referred to as hypothyroidism.

Wikipedia : 72 Hyperthyroidism is the condition that occurs due to excessive production of thyroid hormone by the... more...

Related Diseases for Hyperthyroidism

Diseases in the Hyperthyroidism family:

Familial Hyperthyroidism Due to Mutations in Tsh Receptor

Diseases related to Hyperthyroidism via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 361)
# Related Disease Score Top Affiliating Genes
1 graves' disease 32.3 CTLA4 GNAS LMOD1 SERPINA7 TG THRB
2 myxedema 32.3 CTLA4 TG TPO TSHR
3 graves disease 1 32.2 SERPINA7 TG THRB TPO TRH TSHR
4 struma ovarii 32.1 TG TSHR
5 pituitary tumors 31.3 GH1 GNAS PRL SST
6 mccune-albright syndrome 31.3 BGLAP GH1 GNAS PRL SST
7 plummer's disease 31.2 SHBG TG THRB TPO
8 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 31.1 CTLA4 TG TPO TSHR
9 hypothyroidism 30.9 LEP PRL SERPINA7 SHBG TG TPO
10 nodular goiter 30.9 TG TPO TSHR
11 thyroiditis 30.6 CTLA4 SERPINA7 TG THRB TPO TRH
12 multinodular goiter 30.5 GNAS TG TPO TSHR
13 hashimoto thyroiditis 30.4 CTLA4 TG TPO TSHR
14 neonatal hypothyroidism 30.3 TG TPO TSHR
15 exophthalmos 30.3 PRL TG TSHR
16 thyroid cancer 30.2 GNAS TG THRB TPO TSHR
17 congenital hypothyroidism 30.1 TG TPO TSHR
18 benign struma ovarii 30.0 TG TSHR
19 subacute thyroiditis 29.9 SERPINA6 SERPINA7 SHBG TG TPO TSHR
20 pernicious anemia 29.9 SST TG TPO
21 papillary carcinoma 29.8 TG TPO TSHR
22 goiter 29.8 BGLAP GNAS SERPINA7 TG THRB TPO
23 adenoma 29.8 GH1 GNAS PRL SST
24 endemic goiter 29.7 SERPINA7 TG TPO TSHR
25 differentiated thyroid carcinoma 29.6 BGLAP TG TPO TSHR
26 hypoadrenalism 29.5 GH1 SHBG TG
27 celiac disease 1 29.5 CTLA4 GHRL TG TPO
28 hyperthyroxinemia 29.5 SERPINA7 TPO TRH TSHR
29 chromophobe adenoma 29.4 GH1 PRL SERPINA7 TRH
30 gynecomastia 29.3 CGA PRL SHBG
31 craniopharyngioma 29.2 GHRL PRL TRH
32 thyroid cancer, nonmedullary, 2 29.2 LMOD1 SST TG THRB TPO TSHR
33 prolactin producing pituitary tumor 29.2 PRL SST
34 nontoxic goiter 29.1 BGLAP SERPINA7 SHBG TG TPO TSHR
35 amenorrhea 29.1 LEP PRL SHBG TRH
36 body mass index quantitative trait locus 11 29.1 GH1 GHRL GNAS LEP SHBG
37 pituitary adenoma 29.0 GH1 GNAS PRL SST TRH
38 glucose intolerance 29.0 GH1 GHRL LEP SHBG
39 hyperpituitarism 28.9 GH1 PRL SST TRH
40 bulimia nervosa 2 28.8 GH1 GHRL LEP PRL
41 fibrous dysplasia 28.8 BGLAP GH1 GNAS PRL SST
42 hyperprolactinemia 28.6 GH1 PRL SST TRH
43 insulin-like growth factor i 28.4 BGLAP GH1 LEP PRL SHBG SST
44 acromegaly 28.1 GH1 GHRL GNAS PRL SST TRH
45 hyperthyroidism, familial gestational 12.5
46 hyperthyroidism, nonautoimmune 12.4
47 familial hyperthyroidism due to mutations in tsh receptor 12.2
48 congenital craniosynostosis maternal hyperthyroiditis 11.9
49 thyroid hormone resistance, selective pituitary 11.7
50 thyrotoxic periodic paralysis 11.4

Graphical network of the top 20 diseases related to Hyperthyroidism:



Diseases related to Hyperthyroidism

Symptoms & Phenotypes for Hyperthyroidism

GenomeRNAi Phenotypes related to Hyperthyroidism according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased HPV16-GFP infection GR00350-A 8.92 GNAS SDHA SERPINA7 TRH

MGI Mouse Phenotypes related to Hyperthyroidism:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 9.7 TG THRB TPO TRH TSHR CGA
2 homeostasis/metabolism MP:0005376 9.47 TG THRB TPO TRH TSHR CGA

Drugs & Therapeutics for Hyperthyroidism

PubMedHealth treatment related to Hyperthyroidism: 59

The main treatments for hyperthyroidism include medication to lower production of thyroid hormones (antithyroid drugs), surgery to remove thyroid gland tissue, and radioiodine therapy. The choice of treatment depends on various factors. For example, radioiodine therapy is particularly suitable for people whose thyroid gland has not become too enlarged.Radioiodine therapy involves swallowing radioactive iodine (radioiodine), which collects in the overactive thyroid gland to slow the production of thyroid hormones. Radioiodine can be taken in capsules or dissolved in water. The amount of radiation is very low and most of it leaves the body within a few days. Still, people taking radioiodine should avoid very close contact with others for one to two days. In Germany, it is common to stay at the hospital for a few days after starting therapy. Radioiodine therapy is not suitable for pregnant women.Treatment of an overactive thyroid can cause hypothyroidism (an underactive thyroid). This may happen if the production of thyroid hormones is lowered too far. Once this happens, thyroid hormone replacement therapy will most likely be needed for the rest of your life. The risk of hypothyroidism and other side effects makes treating an overactive thyroid a balancing act.

Drugs for Hyperthyroidism (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 225)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetylcholine Approved Phase 4,Phase 2,Phase 3 51-84-3 187
2
Prednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3 50-24-8 5755
3
Iodine Approved, Investigational Phase 4,Phase 2,Phase 3 7553-56-2 807
4
Propylthiouracil Approved, Investigational Phase 4,Phase 3,Phase 2 51-52-5 657298
5
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
6
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3 83-43-2 6741
7
Prednisone Approved, Vet_approved Phase 4,Phase 2,Phase 3 53-03-2 5865
8
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 1 50-02-2 5743
9
Methotrexate Approved Phase 4 1959-05-2, 59-05-2 126941
10
Diclofenac Approved, Vet_approved Phase 4,Phase 3 15307-86-5 3033
11
Metoprolol Approved, Investigational Phase 4 51384-51-1, 37350-58-6 4171
12
Propranolol Approved, Investigational Phase 4,Phase 3 525-66-6 4946
13
rituximab Approved Phase 4,Phase 2,Phase 3,Phase 1 174722-31-7 10201696
14
Ephedrine Approved Phase 4,Phase 2 299-42-3 9294
15
Pseudoephedrine Approved Phase 4,Phase 2 90-82-4 7028
16
Bimatoprost Approved, Investigational Phase 4,Phase 3 155206-00-1 5311027
17
Dinoprost Tromethamine Approved, Vet_approved Phase 4 38562-01-5 5282415
18
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741 24759
19
leucovorin Approved, Nutraceutical Phase 4 58-05-9 143 6006
20
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 2 1406-16-2
21
Calcitriol Approved, Nutraceutical Phase 4 32222-06-3 5280453 134070
22
Alfacalcidol Approved, Nutraceutical Phase 4,Phase 2 41294-56-8 5282181
23
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
24
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 1 59-30-3 6037
25
Dinoprost Investigational Phase 4 551-11-1 5283078
26 triamcinolone acetonide Phase 4
27 cadexomer iodine Phase 4,Phase 2,Phase 3
28 Prednisolone acetate Phase 4,Phase 2,Phase 3
29 glucocorticoids Phase 4,Phase 2,Phase 3,Phase 1
30 abobotulinumtoxinA Phase 4,Phase 2,Phase 3
31 Methylprednisolone acetate Phase 4,Phase 2,Phase 3
32 Methylprednisolone Hemisuccinate Phase 4,Phase 2,Phase 3
33 Micronutrients Phase 4,Phase 2,Phase 3,Phase 1
34 Cholinergic Agents Phase 4,Phase 2,Phase 3
35 Neuromuscular Agents Phase 4,Phase 2,Phase 3
36 Gastrointestinal Agents Phase 4,Phase 2,Phase 3,Phase 1
37 Neuroprotective Agents Phase 4,Phase 2,Phase 3
38 Neurotransmitter Agents Phase 4,Phase 2,Phase 3
39 Trace Elements Phase 4,Phase 2,Phase 3,Phase 1
40 Triamcinolone diacetate Phase 4
41 Triamcinolone hexacetonide Phase 4
42 Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1
43 onabotulinumtoxinA Phase 4,Phase 2,Phase 3
44 Hormones Phase 4,Phase 2,Phase 3,Phase 1
45 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1
46 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1
47 Antiemetics Phase 4,Phase 2,Phase 3,Phase 1
48 Anti-Infective Agents Phase 4,Phase 2,Phase 3,Phase 1
49 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1
50 Prednisolone hemisuccinate Phase 4,Phase 2,Phase 3

Interventional clinical trials:

(show top 50) (show all 184)

# Name Status NCT ID Phase Drugs
1 Assessment of Intellectual, Psychological and Behavioural Developments Between 6 and 9 Years of the Children Born to Hyperthyroid Mothers During Their Pregnancy Unknown status NCT01779817 Phase 4
2 The Effect of Early Total Thyroidectomy in the Course of Graves' Orbitopathy Unknown status NCT01056419 Phase 4 Propylthiouracil
3 A Prospective, Randomized Trial of Intravenous Pulse Versus Sequential Steroid Therapy for Patients With Graves' Orbitopathy Unknown status NCT01969019 Phase 4 methylprednisolone, prednisone
4 Heart Rate Variability and Hyperthyroidism: Evaluation of the Short-term Effects of Propanolol Completed NCT03393728 Phase 4 Propanolol
5 Block-replacement Therapy During Radioiodine Therapy Completed NCT00150124 Phase 4 MTZ+LT4;Methimazole
6 Antithyroid Drugs During Radioiodine Therapy Completed NCT00150137 Phase 4 Methimazole
7 Impact of SSKI Pre-Treatment on Blood Loss in Thyroidectomy for Graves Disease Completed NCT00946296 Phase 4 Potassium Iodide
8 Prevention Relapse of Graves' Disease by Intrathyroid Injection of Dexamethasone Completed NCT00917241 Phase 4 MMI combined with IID;MMI
9 Effect of Hormone Replacement Therapy on Lupus Activity Completed NCT00392093 Phase 4 Conjugated equine estrogens 0.625 mg/d + MPA 5 mg/d/10d
10 Compare the Efficacy of Cinacalcet vs Traditional Vitamin D for Secondary Hyperparathyroidism (SHPT) Among Subjects Undergoing Hemodialysis Completed NCT01181531 Phase 4 Traditional Vitamin D Therapy;Cinacalcet
11 Prostaglandin F2-alpha Eye Drops in Thyroid Eye Disease (Bima Study) Completed NCT02059655 Phase 4 Bimatoprost;Eye drop solution
12 Adjuvant Treatment of Graves´ Ophthalmopathy With NSAID (aGO Study) Completed NCT01458600 Phase 4 Diclofenac;Methimazole;L-thyroxin;Propranolol;Metoprolol
13 Treatment of Upper Eyelid Retraction Related to Thyroid-associated Ophthalmopathy Using Subconjunctival Triamcinolone Injections Completed NCT01599273 Phase 4 subconjunctival triamcinolone injection
14 Is the Routine Pressure Dressing After Thyroidectomy Necessary? Completed NCT00400465 Phase 4
15 Thermogenesis in Hyperthyroidism and Effect of Anti-Adrenergic Therapy Recruiting NCT03379181 Phase 4 Propranolol
16 Using A Novel Classification System in Intravenous GCs Therapy of TAO: A Multi-central, Randomized, Open, Superior Trial Recruiting NCT03107078 Phase 4 Glucocorticoids
17 Rituximab (RTX) Therapy in Patients With Active TAO Recruiting NCT02378298 Phase 4 Rituximab;Iv Methylprednisolone;peroral methylprednisolone and Methotrexate
18 Hyaluronic Acid Gels for Upper Lid Retraction in Active Stage Thyroid Eye Disease Recruiting NCT01738243 Phase 4 Hyaluronic Acid Gel injection;Saline injection
19 Effects of Statins in Graves' Orbitopathy (GO) in Hypercholesterolemic Patients Not yet recruiting NCT03110848 Phase 4 Atorvastatin;Methylprednisolone
20 A Trial to Evaluate the Efficacy of Orbital Radiotherapy in Graves' Orbitopathy Not yet recruiting NCT03098225 Phase 4 Methylprednisolone
21 Combined Radiotherapy and Intravenous Steroids for Early Progressive Thyroid Eye Disease Not yet recruiting NCT02339142 Phase 4 intravenous corticosteroids (methylprednisolone)
22 The Secondary Beneficial Effects of Prostaglandin Analog Treatment in Thyroid Eye Disease Patients. Withdrawn NCT01927406 Phase 4 Prostaglandin Analog;Timolol
23 Use of Botox in the Management of Thyroid Related Upper Eyelid Retraction Withdrawn NCT01272414 Phase 4 Botulinum Toxin Type A;Saline injection
24 Prednisone Versus Doxycycline in the Treatment of Graves' Orbitopathy Unknown status NCT01809444 Phase 2, Phase 3 Prednisone+placebo of Doxycycline;Doxycycline+placebo of Prednisone
25 Effect of Percutaneous Botulinum Toxin A Injection on Natural Course of Upper Lid Retraction in Thyroid Eye Disease Unknown status NCT00370734 Phase 2, Phase 3 Botulinum toxin A injection
26 Comparison of Different Doses of 131I in Severe Graves' Hyperthyroidism Completed NCT01039818 Phase 3
27 Early Administration of L-carnitine in Hemodialysis Patients Completed NCT00322322 Phase 3 L-Carnitine
28 Low Salt Diet in Idiopathic Hypercalciuria Completed NCT01005082 Phase 2, Phase 3
29 Percutaneous Radiofrequency Thermal Ablation in Compressive Thyroid Nodules Completed NCT01649206 Phase 3
30 Antithyroid Drug Treatment of Thyrotoxicosis in Young People Completed NCT01436994 Phase 3 carbimazole;propylthiouracil;thyroxine
31 Treatment of Soft Tissue Expansion in Inactive Thyroid Eye Disease Patients Using Drops of Prostaglandin Analogues Completed NCT02155049 Phase 3 bimatoprost 0.03%
32 Tocilizumab Treatment in Graves´ Ophthalmopathy (Graves´ Orbitopathy or Thyroid Eye Disease) Completed NCT01297699 Phase 3 Tocilizumab (RoActemra®);Sterile 0.9% Sodium Chloride
33 Assessing the Impact of the Early and Systematic Hormonal Replacement After Radio-isotopic Ablation of Graves'hyperthyroïdism on Quality of Life, Efficiency and Tolerance Completed NCT01295333 Phase 3 the early prophylactic introduction of low dose of LT4 (50 µg/d) at 15 days post-ablation;The initiation of LT4 as soon as the first biological signs of hypothyroidism.
34 Trial of Rituximab for Graves' Ophthalmopathy Completed NCT00595335 Phase 2, Phase 3 Rituximab;Saline;Methylprednisolone
35 Efficacy and Safety of Cholestyramine and Prednisolone as Adjunctive Therapy in Treatment of Overt Hyperthyroidism Recruiting NCT03303053 Phase 3 Cholestyramine Powder 4g;Prednisolone;Standard treatment
36 Treatment of Graves' Orbitopathy (Thyroid Eye Disease) to Reduce Proptosis With Teprotumumab Infusions in a Randomized, Placebo-Controlled, Clinical Study Recruiting NCT03298867 Phase 3
37 Total Thyroidectomy Versus Thionamides in Patients With Moderate-to-Severe Graves' Ophthalmopathy Recruiting NCT03066076 Phase 3 Antithyroid Drug
38 Treatment of Graves´Ophthalmopathy With Diclofenac or Simvastatin (GO-DS) Recruiting NCT03131726 Phase 3 Simvastatin 40mg;Diclofenac Potassium 50 MG
39 Bupivacaine Injection of Eye Muscles to Treat Strabismus Recruiting NCT01616108 Phase 2, Phase 3 Bupivacaine
40 The Effect of Intravenous Glucocorticoids on the Tearfilm in Eyes With Thyroid-associated Ophthalmopathy Recruiting NCT01579539 Phase 3 Methylprednisolone;Esomeprazole
41 Early Levothyroxine Post Radioactive Iodine Active, not recruiting NCT01950260 Phase 2, Phase 3 Levothyroxine
42 The Effect of a New Antioxidant Combination (ASTED) on Moderate to Severe Thyroid Eye Disease Not yet recruiting NCT02422368 Phase 2, Phase 3 Methylprednisolone + ASTED;Methylprednisolone +Placebo
43 The Effect of a New Antioxidant Combination (ASTED) on Mild Thyroid Eye Disease (TED) Not yet recruiting NCT02393183 Phase 2, Phase 3 ASTED
44 Treatment of Graves' Orbitopathy to Reduce Proptosis With Teprotumumab Infusions in an Open-Label Clinical Extension Study Not yet recruiting NCT03461211 Phase 3
45 Role of the Microbiome in Graves' Orbitopathy Unknown status NCT02373995 Phase 1, Phase 2
46 Doxycycline Treatment in Mild Graves' Orbitopathy Unknown status NCT02203682 Phase 2 Doxycycline;placebo
47 LDL-Cholesterol Lowering Effect of KB2115 as Add on to Statin Completed NCT00593047 Phase 2 KB2115
48 Eprotirome for the Treatment of Dyslipidemia, Efficacy and Safety 12-Week, Phase ii Study to Assess the Safety and Efficacy of KB2115 in Patients With Primary Hypercholesterolemia Completed NCT00776321 Phase 2 Eprotirome;Placebo
49 rhTSH, Thyroid Size, and Radioiodine Therapy in Benign Goiter Completed NCT00145366 Phase 2 Recombinant human thyrotropin (Thyrogen)
50 LDL-Cholesterol Lowering Effect of KB2115 as Add on to Ezetimibe Completed NCT00677248 Phase 2 Ezetimibe and placebo;Eprotirome and ezetimibe

Search NIH Clinical Center for Hyperthyroidism

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cochrane evidence based reviews: hyperthyroidism

Genetic Tests for Hyperthyroidism

Genetic tests related to Hyperthyroidism:

# Genetic test Affiliating Genes
1 Hyperthyroidism 28

Anatomical Context for Hyperthyroidism

MalaCards organs/tissues related to Hyperthyroidism:

38
Thyroid, Eye, Bone, Heart, Testes, Kidney, Pituitary

Publications for Hyperthyroidism

Articles related to Hyperthyroidism:

(show top 50) (show all 1210)
# Title Authors Year
1
Both experimental hypothyroidism and hyperthyroidism increase cardiac irisin levels in rats. ( 29405728 )
2018
2
Effects of the dopamine D<sub>3</sub>receptor agonist 7-hydroxy-2-(di-N-propylamino) tetralin in hyperthyroidism-induced premature ejaculation rat model. ( 29369372 )
2018
3
Adult-Onset Sleepwalking Secondary to Hyperthyroidism: Polygraphic Evidence. ( 29246269 )
2018
4
High-dose biotin in infants mimics biochemical hyperthyroidism with some commercial assays. ( 29314108 )
2018
5
Clinicopathological features and comorbidities of cats with mild, moderate or severe hyperthyroidism: a radioiodine referral population. ( 29432704 )
2018
6
Evaluation of Serum Symmetric Dimethylarginine Concentration as a Marker for Masked Chronic Kidney Disease in Cats With Hyperthyroidism. ( 29377360 )
2018
7
A Case of Heart Failure with Hyperthyroidism Demonstrating Discrepancy between the Clinical Course and B-type Natriuretic Peptide Levels. ( 29434126 )
2018
8
Effect of Goiter Dispersion Formula on Serum Cytokines in Hyperthyroidism Patients with Neurologic Manifestations of Graves' Disease: A Randomized Trial on 80 Cases. ( 29406821 )
2018
9
Differential effects of experimental hyperthyroidism on declined immunity of broiler chicken. ( 29327786 )
2018
10
Rapid Remission of Graves' Hyperthyroidism Without Thionamides Under Immunosuppressive Treatment for Concomitant Autoimmune Hepatitis. ( 29336235 )
2018
11
A patient-specific treatment model for Graves' hyperthyroidism. ( 29310665 )
2018
12
Prevalence and risk factors for hyperthyroidism in Irish cats from the greater Dublin area. ( 29372047 )
2018
13
Does hyperthyroidism worsen prognosis of thyroid carcinoma? A retrospective analysis on 2820 consecutive thyroidectomies. ( 29357932 )
2018
14
Association of Hyperthyroidism and Thyroid Autoantibodies with Moyamoya Disease and Its Stroke Event: A Population-based Case-control Study and Meta-analysis. ( 29353860 )
2018
15
Recurrent Graves' hyperthyroidism after prolonged radioiodine-induced hypothyroidism. ( 28944001 )
2017
16
Differential regulation of monocarboxylate transporter 8 expression in thyroid cancer and hyperthyroidism. ( 28576880 )
2017
17
Efficacy of Once Daily versus Divided Daily Administration of Low Daily Dosage (15a88mg/Day) of Methimazole in the Induction of Euthyroidism in Graves' Hyperthyroidism: A Randomized Controlled Study. ( 29403532 )
2017
18
Takotsubo Myocardiopathy and Hyperthyroidism: A Case Report and Literature Review. ( 28781361 )
2017
19
Hyperthyroidism and sick sinus syndrome, a rare but challenging association: A study of three cases. ( 28891553 )
2017
20
The effect of short-term treatment with lithium carbonate on the outcome of radioiodine therapy in patients with long-lasting Graves' hyperthyroidism. ( 28895066 )
2017
21
Subclinical Hyperthyroidism and the Cardiovascular Disease. ( 28915531 )
2017
22
ST-segment elevation acute myocardial infarction associated with hyperthyroidism: beware of coronary spasm! ( 28858949 )
2017
23
Dyschromatosis symmetrica hereditaria with cutaneous lupus erythematosus and hyperthyroidism. ( 28496371 )
2017
24
An FSH and TSH pituitary adenoma, presenting with precocious puberty and central hyperthyroidism. ( 28721217 )
2017
25
Multifocal oral melanoacanthoma associated with Addison's disease and hyperthyroidism: a case report. ( 28658350 )
2017
26
Clinical efficacy of Yingliu mixture combined with metimazole for treating diffuse goitre with hyperthyroidism and its impact on related cytokines. ( 27927064 )
2017
27
A Case With Deteriorating Palmoplantar Pustulosis and Hyperthyroidism After Simultaneous Bimaxillary Orthognathic Surgery. ( 28858556 )
2017
28
MOK, a pharmacopuncture medicine, regulates thyroid dysfunction in L-thyroxin-induced hyperthyroidism in rats through the regulation of oxidation and the TRPV1 ion channel. ( 29246135 )
2017
29
Sex-specific phenotypes of hyperthyroidism and hypothyroidism in aged mice. ( 29273081 )
2017
30
Atrial fibrillation and hyperthyroidism: A literature review. ( 28822529 )
2017
31
Thyrotoxic periodic paralysis: an unusual presentation of hyperthyroidism. ( 29219824 )
2017
32
Struma Ovarii With Hyperthyroidism. ( 28394842 )
2017
33
Survival times for cats with hyperthyroidism treated with a 3.35 mCi iodine-131 dose: a retrospective study of 96 cases. ( 28699814 )
2017
34
Prevalence of and risk factors for feline hyperthyroidism in South Africa. ( 28826266 )
2017
35
Iodine concentration calculated by dual-energy computed tomography (DECT) as a functional parameter to evaluate thyroid metabolism in patients with hyperthyroidism. ( 28724406 )
2017
36
Hyperthyroidism and the Heart. ( 28740583 )
2017
37
Changes in Resting-State Cerebral Activity in Patients with Hyperthyroidism: A Short-Term Follow-Up Functional MR Imaging Study. ( 28878279 )
2017
38
Myopathy in hyperthyroidism as a consequence of rapid reduction of thyroid hormone: A case report. ( 28746208 )
2017
39
Anaesthetic Implications of Severe Hyperthyroidism Secondary to Molar Pregnancy: A Case Report and Review of Literature. ( 29284889 )
2017
40
Liquid treatment for hyperthyroidism in cats is a popular option. ( 29246988 )
2017
41
Effects of electromagnetic fields on bone loss in hyperthyroidism rat model. ( 27973686 )
2017
42
Hypokalemic Paralysis Complicated by Concurrent Hyperthyroidism and Hyperaldosternoism: A Case Report. ( 28050008 )
2017
43
Iron metabolism in patients with Graves' hyperthyroidism. ( 28833367 )
2017
44
Hyperthyroidism in Patients with Graves' Ophthalmopathy, and Thyroidal, Skeletal and Eye Muscle Specific Type 2 Deiodinase Enzyme Activities. ( 28750432 )
2017
45
Liquid formula improves compliance in cats with hyperthyroidism. ( 28733514 )
2017
46
Evaluation of ambulatory arterial stiffness index in hyperthyroidism ( 29306234 )
2017
47
Novel germline mutation (Leu512Met) in the thyrotropin receptor gene (TSHR) leading to sporadic non-autoimmune hyperthyroidism. ( 28195550 )
2017
48
Tremelimumab-Induced Graves Hyperthyroidism. ( 28785544 )
2017
49
Effects of Hyperthyroidism on Coronary Artery Disease: AA Computed Tomography Angiography Study. ( 28867263 )
2017
50
Comparative Effectiveness of Treatment Choices for Graves' Hyperthyroidism - A Historical Cohort Study. ( 28049375 )
2017

Variations for Hyperthyroidism

Expression for Hyperthyroidism

Search GEO for disease gene expression data for Hyperthyroidism.

Pathways for Hyperthyroidism

Pathways related to Hyperthyroidism according to GeneCards Suite gene sharing:

(show all 11)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.92 CGA GH1 GHRL GNAS LEP PRL
2
Show member pathways
12.6 CGA CTLA4 TG TPO TSHR
3
Show member pathways
12.31 CGA GNAS SERPINA7 TG TPO TSHR
4
Show member pathways
12.25 CGA GH1 LEP PRL
5
Show member pathways
11.93 CGA GH1 GHRL LEP
6 11.52 BGLAP CGA PRL
7 11.41 CGA GNAS TSHR
8 11.23 CGA GNAS TSHR
9 11.09 BGLAP CGA THRB
10 10.59 CGA TSHR
11 9.8 CGA TG TPO TRH TSHR

GO Terms for Hyperthyroidism

Cellular components related to Hyperthyroidism according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.65 BGLAP GH1 GHRL LEP PRTN3 SERPINA6
2 extracellular region GO:0005576 9.47 BGLAP CGA GH1 GHRL GNAS LEP
3 endosome lumen GO:0031904 9.16 GH1 PRL

Biological processes related to Hyperthyroidism according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 cell-cell signaling GO:0007267 9.81 CGA SST TRH TSHR
2 response to ethanol GO:0045471 9.7 BGLAP LEP TRH
3 female pregnancy GO:0007565 9.63 GNAS LEP PRL
4 response to nutrient levels GO:0031667 9.5 BGLAP GHRL LEP
5 energy reserve metabolic process GO:0006112 9.49 GNAS LEP
6 JAK-STAT cascade involved in growth hormone signaling pathway GO:0060397 9.48 GH1 PRL
7 thyroid hormone generation GO:0006590 9.43 CGA TPO
8 positive regulation of multicellular organism growth GO:0040018 9.43 GH1 GHRL TSHR
9 hormone biosynthetic process GO:0042446 9.4 TG TPO
10 adult feeding behavior GO:0008343 9.37 GHRL LEP
11 hormone-mediated signaling pathway GO:0009755 9.33 GHRL TRH TSHR
12 regulation of receptor activity GO:0010469 9.23 CGA GH1 GHRL LEP PRL SST
13 positive regulation of JAK-STAT cascade GO:0046427 9.13 GH1 LEP PRL

Molecular functions related to Hyperthyroidism according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 9.23 CGA GH1 GHRL LEP PRL SST
2 prolactin receptor binding GO:0005148 8.96 GH1 PRL

Sources for Hyperthyroidism

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....